Home » Stocks » GMED

Globus Medical, Inc. (GMED)

Stock Price: $59.87 USD 1.40 (2.39%)
Updated November 24, 4:00 PM EST - Market closed
Pre-market: $58.50 -1.37 (-2.29%) Nov 25, 7:00 AM

Stock Price Chart

Key Info

Market Cap 5.91B
Revenue (ttm) 767.26M
Net Income (ttm) 94.86M
Shares Out 76.24M
EPS (ttm) 0.93
PE Ratio 64.38
Forward PE 28.33
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $59.87
Previous Close $58.47
Change ($) 1.40
Change (%) 2.39%
Day's Open 58.82
Day's Range 58.51 - 60.17
Day's Volume 847,026
52-Week Range 33.41 - 60.17

More Stats

Market Cap 5.91B
Enterprise Value 5.50B
Earnings Date (est) Feb 24, 2021
Ex-Dividend Date n/a
Shares Outstanding 76.24M
Float 75.43M
EPS (basic) 0.96
EPS (diluted) 0.93
FCF / Share 1.10
Dividend n/a
Dividend Yield n/a
Earnings Yield 1.55%
FCF Yield 1.82%
Payout Ratio n/a
Shares Short 2.18M
Short Ratio 3.58
Short % of Float 2.89%
Beta 0.96
PE Ratio 64.38
Forward PE 28.33
P/FCF Ratio 54.94
PS Ratio 7.70
PB Ratio 3.95
Revenue 767.26M
Operating Income 102.88M
Net Income 94.86M
Free Cash Flow 107.53M
Net Cash 409.64M
Net Cash / Share 4.15
Gross Margin 78.90%
Operating Margin 13.41%
Profit Margin 12.40%
FCF Margin 14.01%
ROA 4.46%
ROE 6.88%
ROIC 10.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (15)

Buy 9
Overweight 0
Hold 5
Underweight 1
Sell 0

Analyst Consensus: Buy

Price Target

(2.24% upside)
Current: $59.87
Target: 61.21
*Average 12-month price target from 14 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth10.15%12.11%12.76%3.53%14.84%9.19%12.56%16.45%15.02%-
Gross Profit605554486429412364334311263234
Operating Income17216916215417213810211597.3687.69
Net Income15515610710411392.4968.6173.8360.7854.46
Shares Outstanding99.1597.8896.2495.6595.0594.2392.6589.6188.1188.93
Earnings Per Share1.521.541.
EPS Growth-1.3%40%1.85%-7.69%20.62%32.88%-8.75%19.4%11.67%-
Operating Cash Flow17218215914812479.1793.4776.5276.4171.29
Capital Expenditures-70.75-54.70-51.30-40.91-50.76-24.75-23.68-24.68-22.49-12.30
Free Cash Flow10112710810773.2554.4269.7951.8453.9258.99
Cash & Equivalents311340374291307252239212143112
Total Debt---------5.25
Net Cash / Debt311340374291307252239212143106
Book Value1,4021,186968832715585472387282228
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Globus Medical, Inc.
Country United States
Employees 2,000
CEO David M. Demski

Stock Information

Ticker Symbol GMED
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Medical Devices
Unique Identifier NYSE: GMED
IPO Date August 3, 2012


Globus Medical, a medical device company, focuses on the development and commercialization of implants that heal patients with musculoskeletal disorders. Its spine product portfolio includes a range of implant and surgical approach options that can be used to treat degenerative, deformity, tumor, and trauma conditions affecting the spine from the occiput to the sacrum. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and regenerative biologic products, such as allografts and synthetic alternatives that are adjunctive treatments used in combination with stabilizing implant hardware. In addition, it provides motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous distraction devices, and interventional pain management solutions to treat vertebral compression fractures; imaging, navigation, and robotic assisted surgery technology solutions; and hip and knee joint solutions, as well as distributes human cell, tissue, and cellular and tissue based products. Further, the company offers expandable spacer products, which include RISE, RISE-L, CALIBER, CALIBER-L, ALTERA, ELSA, ELSA-ATP, SABLE, MAGNIFY, MAGNIFY-S, FORTIFY, and XPand; CREO thoracolumbar stabilization platform that offers instruments and implants for treating pathologies; CREO MIS and CREO MCS, options designed for less invasive surgery and minimal muscle disruption; CREO Derotation and CREO Rod Link Reducer systems, which help to streamline various derotation maneuvers for deformity correction; CREO Addition that provides a range of connectors; and CREO Fenestrated, a cement augmented pedicle screw system for patients with advanced stage tumors and limited life expectancy, as well as QUARTEX, an occipito-cervico-thoracic stabilization system. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania.